NCT06299540Recruiting
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 180 (estimated)
- First submitted
- 1 Mar 2024
- Start date
- 27 May 2024
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Janssen Cilag S.A.S.
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT06299540
What you commit to
- Study type: Observational
- Planned participants: 180
- From 27 May 2024 to the primary completion date, 30 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit
Other
- Pregnant participants or planning to become pregnant while enrolled in this study
- Participants with inability or deemed unsafe to practice physical activity
- Participants who are currently involved in an interventional study
- Participants with probable difficulties in using the digital tool autonomously
Who the study is looking for
- Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)
- Participants agreed to follow the individual physical activity intervention (IPAI)
- Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet
- Participants with Internet access at home and email address
- Participants agreed to wear a connected watch 24 hours a day for all the duration of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Universitaire du Cancer Toulouse - Oncopole Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.